Company Profile

ERIS LIFESCIENCES LTD.

NSE : ERISBSE : 540596ISIN CODE : INE406M01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE444.30-2.55 (-0.57 % )
PREV CLOSE (Rs.) 446.85
OPEN PRICE (Rs.) 450.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1912
TODAY'S LOW / HIGH (Rs.)443.80 454.60
52 WK LOW / HIGH (Rs.)341.05 593.4
NSE445.15 -1.85 (-0.41 % )
PREV CLOSE(Rs.) 447.00
OPEN PRICE (Rs.) 451.85
BID PRICE (QTY) 445.15 (94 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 41197
TODAY'S LOW / HIGH(Rs.) 444.00 454.80
52 WK LOW / HIGH (Rs.)321 595

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 8.57854
Dividend Yield(%)
TTM EPS (Rs.)
P/E Ratio
Book Value (Rs.)
Face Value (Rs.)
MCap (Rs. in Mn)
Price/Earning (TTM)
Price/Sales (TTM)
Price/Book (MRQ)
PAT Margin (%) 31.83
ROCE (%) 25.98
Incorporation Year : 2007

Management Info :

- Chairman Amit Indubhushan Bakshi - Managing Director

Registered Office :

Address : 8th Floor, Commerce House I V,Beside Shell Petrol Pump,100 Feet Road, Prahladnagar,
Ahmedabad,
Gujarat-380015

Phone : 079 3045 1111

Website : www.eris.co.in

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS More
16Jun06-16-2020$Eris Life sciences informs about clarification on rise in volume Eris Life sciences informs a

With reference to the NSE Letter no. NSE/CM/Surveillance/9623 dated 15th June, 2020, Eris Lifesciences has informed that there is no such announcement or price sensitive information, which is pending to be intimated by the Company to the stock exchanges concerning its performance/ operations. The company reiterated and clarified that all the latest relevant information about the Company, which in its opinion may have a bearing on the price/ volume behavior in the scrip has already been disclosed to the Exchanges. Further, the Company is in compliance with the SEBI (Listing Obligations and disclosures Requirements) Regulations and shall keep the stock exchanges duly informed of all the price sensitive information(s) in future as well.

The above information is a part of company’s filings submitted to BSE.

With reference to the NSE Letter no. NSE/CM/Surveillance/9623 d..
04Jun06-04-2020$Eris Lifesciences incorporates subsidiary company Eris Lifesciences incorporat
Eris Lifesciences, through its wholly owned subsidiary company namely Eris Healthcare, has incorporated a subsidiary company ‘Eris Pharmaceuticals’ on June 02, 2020. Eris Pharmaceuticals has been incorporated as a subsidiary of Eris Healthcare for carrying out business related to pharmaceuticals products.

Eris Lifesciences is engaged in manufacturing, marketing and selling of branded generics within the chronic and acute categories of the Indian Pharmaceutical Market.
Eris Lifesciences, through its wholly owned subsidiary company..
11Mar03-11-2020$Eris Lifesciences informs about outcome of board meeting Eris Lifesciences informs ab

Eris Lifesciences has informed that the Board of Directors of the Company at their meeting held today, March 11, 2020 duly approved the declaration of Interim Dividend of Rs 2.87 (at the rate of 287%) on each fully paid-up equity share of Re 1 for the Financial Year 2019-20. Further informed that, the Company has fixed 20th March, 2020 as the record date to determine the names of the equity shareholders, who shall be entitled to receive the payment towards interim dividend for the financial year 2019-20. The payment of the interim dividend would be made to the eligible shareholders on or before 10th April, 2020.

The above information is a part of company’s filings submitted to BSE.

Eris Lifesciences has informed that the Board of Directors of t..
08Feb02-08-2020$Eris Lifesciences submits board meeting intimation Eris Lifesciences submits bo

Eris Lifesciences has submitted the board meeting intimation.

The above information is a part of company’s filings submitted to BSE.

Eris Lifesciences has submitted the board meeting intimation.Th..
27Jan01-27-2020$Eris Lifesciences informs about updates on buyback offer Eris Lifesciences informs ab

Axis Capital (Manager to Buyback Offer) has submitted a copy of post Buyback Public Announcement for the attention of the Equity Shareholders/ Beneficial Owners of Equity Shares of Eris Lifesciences (Target Company).

The above information is a part of company’s filings submitted to BSE.

Axis Capital (Manager to Buyback Offer) has submitted a copy of..
Financials More
Rs. in Millions
QTR Mar 20 ANNUAL 20
Net Profit545.822907.59
Gross Profit 590.85 3234.72
Operating Profit 723.313702.15
Net Sales 2307.3710202.31
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Sanofi India (BSE)
 7594.15 (1.05%)
M.Cap ( in Cr)
17489.80
IOL Chem & Pharma (BSE)
 623.65 (7.19%)
M.Cap ( in Cr)
3661.17
Pfizer (BSE)
 4121.65 (0.81%)
M.Cap ( in Cr)
18855.61
Shilpa Medicare (BSE)
 516.80 (5.92%)
M.Cap ( in Cr)
4213.31
Hester Biosciences (BSE)
 1238.35 (1.93%)
M.Cap ( in Cr)
1053.45
Shareholding Pattern More
PROMOTERS 55.55 %
NON-INSTITUTION 23.08 %
MUTUAL FUNDS/UTI 10.51 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes